On January 15, 2025, Be Biopharma, Inc. closed the transaction. The company has amended the terms of the transaction. The company has now raised $10,000,000 in its second and final tranche, bringing total capital raised to $92,000,0000.

The transaction included participation from new investor Nextech Invest Ltd., and returning investors Arch Venture Partners, L.P., Atlas Venture L.P., RA Capital Management, L.P., Alta Partners LP, Longwood Fund, Bristol-Myers Squibb Company, Takeda Ventures, Inc. and others. Melissa McCracken of Nextech Invest Ltd. will join company's board.